United States

Bayer AG (BAYGn.DE)

BAYGn.DE on Xetra

11:35am EST
Change (% chg)

€1.94 (+2.20%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Latest Key Developments (Source: Significant Developments)

Bayer CFO says no need to rush into Covestro share sale
Wednesday, 27 Jul 2016 09:14am EDT 

Bayer : CFO Johannes Dietsch says no need to rush into any Covestro share sale transaction, no need to pile up further cash at the moment . Pharma head Dieter Weinand says have upgraded Xarelto 2016 sales growth target towards 30 percent, for Eylea more than 30 percent . Bayer crop science head Liam Condon says expects slow return to growth in Latam in 2017 . CEO Werner Baumann says will not comment on status of Monsanto proposal because have agreed to private discussions with MonsantoFurther company coverage: [BAYGn.DE] ((frankfurt.newsroom@thomsonreuters.com; +49 69 7565 1270;)).  Full Article

Covestro aiming for at least 1.78 bln eur in FY EBITDA
Tuesday, 26 Jul 2016 02:47am EDT 

Covestro <1COV.DE> CFO to Reuters : Aiming for at least 1.78 billion EUR in EBITDA for the full year, up from an adjusted 1.64 billion in 2015 . Expects no special items in 2016 Further company coverage: [1COV.DE] ((frankfurt.newsroom@thomsonreuters.com; +49 69 7565 1270;)).  Full Article

Monsanto views Bayer's revised proposal as financially inadequate, insufficient to ensure deal certainty
Tuesday, 19 Jul 2016 08:00am EDT 

Monsanto Co : Monsanto views Bayer's revised proposal as financially inadequate and insufficient to ensure deal certainty . Also remains open to conversations with other parties to assess whether a deal board believes is in best interest can be realized .Remains open to continued and constructive conversations with Bayer.  Full Article

Monsanto says has received revised proposal from Bayer
Thursday, 14 Jul 2016 12:40pm EDT 

Monsanto : Monsanto acknowledges revised proposal from bayer . Board of directors of Monsanto will review proposal, in consultation with its financial and legal advisors . Monsanto Co says Morgan Stanley & Co and Ducera Partners are acting as financial advisors ."Monsanto will have no further comment until its board of directors has completed its review".  Full Article

Monsanto said to revive talks with BASF over Bayer alternative - Bloomberg, citing sources
Wednesday, 13 Jul 2016 05:21pm EDT 

: Monsanto said to revive talks with BASF over Bayer alternative - Bloomberg, citing sources . Monsanto is exploring various transactions, including potential acquisition of BASF's agriculture-solutions unit - Bloomberg, citing sources .In return, Ludwigshafen, Germany-based BASF would likely receive newly issued shares in Monsanto - Bloomberg, citing sources.  Full Article

Bayer in deal with X-Chem over DNA-encoded small molecule libraries
Tuesday, 12 Jul 2016 07:05am EDT 

Bayer : Says enters drug discovery collaboration with privately held x-Chem Inc across multiple therapeutic areas . Says X-Chem will receive up-front payment, research and development funding, milestone payments of up to $528 million .Says gets access to DEX drug discovery engine technology, based on DNA-encoded libraries of small molecules.  Full Article

Monsanto seeks up to $7 bln more from Bayer in takeover-Handelsblatt
Wednesday, 29 Jun 2016 01:38pm EDT 

:. The U.S. seed producer has demanded that Germany's Bayer increase its takeover offer by $10-15 per share, unnamed sources tell German business daily Handelsblatt. .. The requested increase would push the valuation of Monsanto up to $67 billion to $69 billion from Bayer's rejected $62 billion. .. Insiders tell the paper Britain's vote to leave the European Union could put Bayer's planned financing of the deal into question as investors might be wary of its planned capital hike of up to 15 billion euros due to market turmoil. ..Monsanto said earlier on Wednesday it is in talks with Bayer and other companies regarding "alternative strategic options," a month after it rejected the German company's $62-billion takeover offer. [nL4N19L3SJ].  Full Article

Monsanto & Bayer CEOs have met, but no progress made toward deal - CNBC
Tuesday, 28 Jun 2016 09:55am EDT 

: Monsanto & Bayer CEOs have met, but no progress made toward deal- CNBC, citing sources (Bengaluru Newsroom) (((+91 80 6749-1130; within U.S. +1 646 223 8780);)).  Full Article

Bayer makes new takeover approach to Monsanto at same price,Monsanto rebuffs new Bayer approach,seeking higher offer-CNBC,citing DJ
Friday, 10 Jun 2016 02:11pm EDT 

: Bayer makes new takeover approach to Monsanto at same price, Monsanto rebuffs new Bayer approach, seeking higher offer - CNBC, citing DJ Further company coverage: [MON.N] (Bengaluru Newsroom) ((+1 646 223 8780;)).  Full Article

Orion and Bayer start new phase III study of prostate cancer drug
Friday, 3 Jun 2016 02:30am EDT 

Orion Oyj : Says Orion and Bayer expand clinical development program for ODM-201 and initiate a new phase III study Arasens in patients with metastatic hormone-sensitive prostate cancer . Says new the study will evaluate the safety and efficacy of the compound in combination with standard androgen deprivation therapy (ADT) and the chemotherapy docetaxel in men with newly diagnosed metastatic hormone-sensitive prostate cancer .Says new trial is expected to start the enrolment of patients towards the end of 2016.  Full Article


Bracco, Guerbet looking for partners for Bayer radiology bids: sources

FRANKFURT Italy's healthcare group Bracco is working on a potential bid for the radiology supplies unit that Germany's Bayer AG wants to sell, people close to the matter said.